Ultragenyx Pharmaceutical Inc.

NasdaqGS:RARE Stock Report

Market Cap: US$3.7b

Ultragenyx Pharmaceutical Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

NasdaqGS:RARE Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
12 Jun 24SellUS$441,270Karah ParschauerIndividual9,806US$45.00
10 Jun 24SellUS$71,391Corazon SandersIndividual1,737US$41.10
02 May 24SellUS$15,456Eric CrombezIndividual354US$43.66
18 Apr 24SellUS$6,262Eric CrombezIndividual142US$44.10
11 Mar 24SellUS$574,644Thomas KassbergIndividual11,509US$49.93
07 Mar 24SellUS$620,443Matthew FustIndividual12,195US$50.89
01 Mar 24SellUS$256,328Erik HarrisIndividual4,768US$53.76
01 Mar 24SellUS$18,332Theodore HuizengaIndividual341US$53.76
01 Mar 24SellUS$224,340John PinionIndividual4,173US$53.76
01 Mar 24SellUS$66,555Eric CrombezIndividual1,238US$53.76
01 Mar 24SellUS$54,351Thomas KassbergIndividual1,011US$53.76
01 Mar 24SellUS$201,923Karah ParschauerIndividual3,756US$53.76
07 Sep 23SellUS$6,249Theodore HuizengaIndividual163US$38.34
05 Sep 23SellUS$227,760Erik HarrisIndividual6,000US$37.96
01 Sep 23SellUS$3,326Theodore HuizengaIndividual87US$38.23

Insider Trading Volume

Insider Buying: RARE insiders have only sold shares in the past 3 months.


Ownership Breakdown

What is the ownership structure of RARE?
Owner TypeNumber of SharesOwnership Percentage
Private Companies1,4620.00162%
State or Government35,0930.0388%
Individual Insiders2,725,2353.01%
General Public5,750,4196.35%
Hedge Funds7,087,1157.83%
Institutions74,906,34082.8%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.8%.


Top Shareholders

Top 25 shareholders own 66.29% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.61%
The Vanguard Group, Inc.
8,700,007US$352.6m0.31%0.01%
7.83%
RTW Investments, LP
7,087,115US$287.2m2.9%4.62%
5.78%
BlackRock, Inc.
5,235,738US$212.2m-0.05%no data
4.53%
Wellington Management Group LLP
4,097,975US$166.1m-7.18%0.02%
4.26%
Sands Capital Management, LLC
3,859,447US$156.4m-6.28%0.38%
3.94%
T. Rowe Price Group, Inc.
3,568,873US$144.6m3.48%0.01%
3.15%
State Street Global Advisors, Inc.
2,851,250US$115.6m-12.3%no data
2.65%
ClearBridge Investments, LLC
2,400,854US$97.3m0.73%0.07%
2.42%
Emil Kakkis
2,190,403US$88.8m-19.6%no data
2.14%
Federated Hermes, Inc.
1,938,680US$78.6m-20.8%0.2%
2.06%
Alkeon Capital Management, LLC
1,867,928US$75.7m0%0.51%
1.96%
Rock Springs Capital Management LP
1,774,938US$71.9m1.19%1.92%
1.85%
Suvretta Capital Management, LLC
1,676,811US$68.0m-21.1%2.81%
1.64%
AllianceBernstein L.P.
1,482,471US$60.1m-6.09%0.02%
1.62%
Baker Bros. Advisors LP
1,466,547US$59.4m0%0.66%
1.48%
Geode Capital Management, LLC
1,339,826US$54.3m4.38%no data
1.33%
Deutsche Asset & Wealth Management
1,207,225US$48.9m2.93%0.02%
1.15%
Pictet Asset Management Limited
1,036,374US$42.0m1.29%0.03%
1.07%
Marshall Wace LLP
968,990US$39.3m-34.9%0.07%
1.03%
Avidity Partners Management, L.P.
933,500US$37.8m10.5%1.48%
1.01%
Dws Investment Gmbh
913,162US$37.0m1.95%0.02%
1%
BNY Asset Management
906,494US$36.7m-9.93%0.01%
0.97%
Emerald Advisers, LLC
873,478US$35.4m0.69%0.78%
0.92%
Avoro Capital Advisors LLC
830,000US$33.6m137%0.39%
0.87%
First Light Asset Management, LLC
790,446US$32.0m6.15%2.82%
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.